Topic Highlight
Copyright ©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Sep 28, 2014; 20(36): 12900-12907
Published online Sep 28, 2014. doi: 10.3748/wjg.v20.i36.12900
Table 2 Treatment parameters and toxicities in phase III studies of postoperative radiotherapy for gastric cancer
Ref.GroupConcurrent chemoRT planningRT dose (Gy)RT targetSevere toxicityCompleted planned treatment
SWOG/INT-0116[3]CRT5FU + LV2D45Tumor bed, LN (Nos. 1-16)G3+, 41%, G4+ 32%(GI, 33%)64%(17 due to toxic effect)
ARTIST[6]CT-CRT-CTCapecitabine2D or 3D45LN (Nos. 7-9 and 12-16)Similar toxicity profile between the two groups (mostly well tolerated)82% (5 due to toxic effect, but 1 during CRT)
NCC, South Korea[7]CRT5FU + LV2D or 3D45Tumor bed, LN (Nos. 1-16)G3+ Hema; 20% vs 25%, G3+ GI; 17% vs 11%87% (2 due to toxic effect)
IMRT, China[8]CRT5FU + LVIMRT45Tumor bed, LN (Nos. 1-16)Similar toxicity profile between the two groups (mostly well tolerated)91% (4 due to toxic effect)